Sharonmoyee Goswami

Goswami’s notable representations include:

• Representation of Illumina in several matters, including:
  • Representing Illumina as plaintiff in a patent infringement lawsuit brought in Delaware federal court against Element Biosciences, concerning next-generation sequencing instruments.
  • Represented Illumina in an administrative challenge brought by the Federal Trade Commission (FTC) concerning Illumina’s $8 billion acquisition of GRAIL, a healthcare company developing a cancer screening test for 50 cancer types. Ms. Goswami obtained an unprecedented trial win, in which the FTC’s Chief Administrative Law Judge ruled in favor of Illumina and rejected the FTC’s challenge to the merger. In connection with this victory, the Cravath team was recognized as The Am Law Litigation Daily’s “Litigators of the Week.”
  • Represented Illumina in antitrust litigation filed by Complete Genomics and related entities in California federal court alleging that Illumina unlawfully asserted certain patents against plaintiffs in an anticompetitive manner. The case settled on grounds favorable to Illumina.

• Representation of Alarm.com in several patent infringement matters, including:
  • Representing Alarm.com on appeal after winning a trial decision in patent infringement litigation brought by Causam Enterprises at the U.S. International Trade Commission (ITC) concerning four patents for demand management functionality used to manage electric operating reserves. The ITC affirmed the trial decision and terminated the investigation, which is currently on appeal to the Federal Circuit. She also represents Alarm.com in similar litigation in Texas federal court.
  • Secured numerous victories for Alarm.com in patent infringement litigation brought by Vivint concerning interactive security and home automation technology, eliminating over 100 claims with respect to five of Vivint’s patents in PTAB decisions and repeatedly knocking back Vivint’s attempts to reverse those rulings on appeal. Following eight years of litigation in multiple jurisdictions, Ms. Goswami helped secure a favorable resolution for Alarm.com to end all litigation between the parties. In connection with her representation, she successfully argued a Federal Circuit appeal against the U.S. Patent and Trademark Office (USPTO), obtaining a precedential opinion in Alarm.com’s favor that offers new guidance regarding the interplay between the ex parte reexamination statute and the inter partes review (IPR) statute. 
  • Won a trial decision for Alarm.com in an ITC investigation initiated by EcoFactor, which sought an exclusion order to prevent certain products, among them Alarm.com’s smart thermostats, from entering the U.S. The matter was brought against Alarm.com and other makers of smart thermostats, and was tried in one of the first all-virtual ITC patent infringement trials.

• Representation of Abiomed, a global medical device company that develops groundbreaking cardiovascular products, in several intellectual property matters, including:
  • Representation of Abiomed in Massachusetts federal court and on appeal to the Federal Circuit in two patent infringement matters against Maquet Cardiovascular relating to guidance systems used in minimally invasive intravascular blood pumps.
  • Represented Abiomed as plaintiff in a trade secret and breach of contract action in Massachusetts federal court against Enmodes and its founder, alleging Enmodes wrongfully disclosed Abiomed’s confidential information and trade secrets. After defeating defendants’ motion to dismiss and moving to dismiss the counterclaims against Abiomed, the parties reached a settlement and stipulated to the dismissal of the action.
  • Secured complete victories for Abiomed in four IPR proceedings and one post-grant proceeding against WhiteSwell Medical relating to patents on devices and methods to treat pulmonary edema.
• Representing Ingevity in its appeal to the Federal Circuit of a patent infringement case against BASF and BASF’s antitrust counterclaims.
• Representing Southern Power Company and Deriva Energy in connection with seven actions brought in North Carolina federal court by the founder and sole shareholder of Trabant Solar alleging infringement of patents relating to free‑standing solar trackers.

• Representing First Solar in multiple patent infringement litigations in Delaware federal court against various competitors concerning solar technology, including JinkoSolar, a Chinese solar module manufacturer; Canadian Solar, a photovoltaics company; and Mundra Solar, an Indian solar module manufacturer.

• Representing Medytox, a manufacturer of Meditoxin, a type of cosmetic botulinum toxin, in its appeal to the Federal Circuit of the final determination issued by the ITC in an action against Hugel, a global medical aesthetics company.

• Representing Adstra, a data software company, as lead counsel in connection with its appeal before the Second Circuit in pending litigation against Kinesso and Acxiom, concerning trade secret misappropriation, breach of contract and other related claims over certain data processor agreements.

• Secured, as lead counsel, a favorable settlement for Tempur Sealy and certain of its subsidiaries in patent infringement litigation brought by Purple Innovation in North Carolina federal court, alleging that Tempur Sealy’s FlexGrid Hybrid mattresses infringed Purple’s patented GelFlex Grid mattress technology.

• Secured favorable settlements for Truist Bank in patent infringement litigation brought by United Services Automobile Association (“USAA”) in Texas federal court concerning patents that relate to remote check deposits for mobile banking, and in associated IPR proceedings. 

• Represented Biogen in litigation concerning its introduction of a biosimilar to Genentech’s rheumatoid arthritis drug Actemra® (tocilizumab) under the Biologics Price Competition and Innovation Act (BPCIA), and secured a settlement relating to the same.

• Represented Amgen in litigation concerning its introduction of a biosimilar to AbbVie’s biologic drug, Humira—one of the world’s largest‑selling drugs—in one of the first cases to proceed under the BPCIA. Amgen reached a global settlement with AbbVie that enabled Amgen to market the first approved biosimilar to Humira in the U.S. and Europe.

• Won a jury verdict for Amgen in a patent infringement case in Delaware federal court against Sanofi and Regeneron relating to Amgen’s patents covering a class of biologic drugs that treat high cholesterol.

• Obtained a jury verdict for DRIT, an investment partnership, in a patent licensing dispute against Glaxo Group over the lupus drug Benlysta®. 

• Represented Qualcomm in a suit filed by the FTC in California federal court alleging violations of Section 5 of the FTC Act and seeking a permanent injunction against Qualcomm. Qualcomm ultimately prevailed in litigation against the FTC.